Do Cannabis Compounds Block COVID? What the Oregon State Study Found

Facebook ↗WhatsApp ↗

Originally published 2022-01-15. Dates, ages and announcements in this article refer to January 2022.

In January 2022, a team led by Richard van Breemen at Oregon State University reported that two acids found in hemp, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), latched onto the spike protein of SARS-CoV-2 and stopped the virus from getting into human cells in laboratory tests. Headlines quickly turned this into “weed prevents COVID.” It does not. The work was done in lab dishes, not in people, and neither smoking cannabis nor buying an ordinary CBD product was tested or recommended.

Cannabis Compounds and SARS-CoV-2 in Laboratory Research

Here is what the study actually found, how the experiment worked, why the compounds involved are not the same as the CBD and THC most people have heard of, and what would have to happen before anyone could call them a treatment.

What the Oregon State study found

The paper appeared in the Journal of Natural Products on 10 January 2022. Van Breemen, who works at Oregon State’s Global Hemp Innovation Center, its College of Pharmacy and the Linus Pauling Institute, carried out the work with colleagues including scientists at Oregon Health & Science University.

Their key results, as described in the university’s own announcement:

  • CBGA and CBDA bound to the SARS-CoV-2 spike protein with the highest affinity of the cannabinoids identified in their screen.
  • In cell experiments, the two compounds prevented the virus from entering human epithelial cells, the kind of cells that line the airways.
  • They worked about equally well against the original virus and two variants circulating at the time, Alpha (B.1.1.7) and Beta (B.1.351).

The study did not compare infection rates between people who took the compounds and people who did not. No human or even animal infection data were part of it.

How the experiment worked

To get into a cell, SARS-CoV-2 uses its spike protein to grab hold of a receptor called ACE2 on the cell’s surface. The spike is the same target that COVID-19 vaccines and antibody treatments are designed around. If something sticks to the spike in the right place, it can, in principle, stop that first handshake.

The team used a screening method developed in van Breemen’s own lab, affinity selection mass spectrometry. In plain terms, they mixed the spike protein with extracts containing many different molecules, washed away everything that did not stick, and then identified what was left. Besides hemp, they screened other plant materials, including red clover, wild yam, hops and three species of licorice.

Once CBGA and CBDA emerged as strong binders, the researchers tested whether they actually blocked live virus from infecting cells in culture. They did. A licorice compound, licochalcone A, also bound the spike, but at the time of the announcement it had not yet been tested against live virus.

CBGA and CBDA are not the CBD in the shop

This is the part most headlines skipped. CBGA and CBDA are the raw, acidic forms of cannabinoids that occur in the living hemp plant. When hemp is heated or processed, they are largely converted into other molecules, such as CBG and CBD. Many commercial hemp products therefore contain little of the acids the study used.

They are also not THC, the compound responsible for the cannabis “high.” Van Breemen stressed the difference, pointing out that the two acids “are not controlled substances like THC.” THC played no role in the findings.

As for smoking, it was never part of the research. Reporting at the time, including coverage summarised by KFF Health News, noted the lead researcher’s position that smoking cannabis offers no protection against the virus. Burning the plant would destroy much of the acidic compounds anyway, and smoke irritates the very airways the virus attacks.

Hemp-derived ingredients do turn up in foods, supplements and cosmetics, and hemp seed is a known source of fibre and protein. None of that means those everyday products contain useful amounts of CBGA or CBDA, or that they protect anyone from infection.

What the researchers said, and the caveats

Van Breemen was optimistic about where the work could lead. In the university’s release he said the compounds “have the potential to prevent as well as treat infection by SARS-CoV-2.” He also noted that they can be taken by mouth and have a history of safe use in humans.

The key word is potential. Several gaps stood between the lab finding and any real-world use:

  • No human data. Cells in a dish do not have a digestive system, a liver or an immune system. A compound that works in culture often fails once it has to be absorbed, distributed and kept at an effective level in the body.
  • Dose unknown. Nobody knew what amount, taken in what form, would reach the airways at a useful concentration, or whether that amount would be safe.
  • Variants. Only the original virus, Alpha and Beta were tested. Later variants such as Delta and Omicron carried further spike mutations, and the study could not say how the compounds would fare against them.
  • Resistance. Van Breemen himself noted that if such compounds were used widely, resistant variants could still emerge, though combining them with vaccination might make that harder.

From a lab result to a medicine

A long list of substances, from common drugs to plant extracts, was reported to block SARS-CoV-2 in laboratory experiments during the pandemic. Only a handful went on to show benefits in properly controlled human trials. That is not because lab research is useless; it is how the pipeline normally works. Screening finds candidates, and later stages filter out the many that do not hold up.

For CBGA or CBDA to become a recognised prevention or treatment, researchers would need animal studies, then human trials that establish safety and dosing, and finally larger trials comparing infection or illness rates against a placebo. As of the study’s publication, none of those steps had been done for this use.

So the fair summary is this: an interesting early result that identified two plant compounds worth studying further, and a good example of how a careful lab finding can be stretched by headlines into a claim the scientists never made.

What this means for you

If you want to protect yourself from COVID-19, the tools with strong evidence behind them remain vaccination and the usual measures recommended by public health agencies. Hemp products are not a substitute. If you are thinking of taking any cannabinoid supplement, particularly alongside other medicines, talk to a doctor or pharmacist first, as some cannabinoids can interact with prescription drugs.

Sources: Oregon State University: research shows hemp compounds prevent coronavirus from entering human cells; Journal of Natural Products paper (PubMed record); KFF Health News: lab study finds certain cannabis compounds may block COVID infection.

COMMENTS